Search

Author/Creator Sebastian, S

21. OC-072 Differences in therapy approaches and outcomes in paediatric and adult onset crohn's disease with perianal fistula: comparison of 2 ecco collaborative multicentre fistula cohorts. (17th June 2017)

Authors:
Tzivinikos, C; Nair, M; Ashton, K; Drskova, T; Sahnan, K; Muhammed, R; Devadason, D; Hradsky, O; Crook, K; Palmer, R; Akbar, A; Thomson, M; Hart, A; Fiorino, G; Black, C; Pugliese, D; Armuzzi, A; Katsanos, K; Christodoulou, D; Maconi, G
Journal:
Gut
Issue:
Volume 66(2017)Supplement 2
Page Start:
A39
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

22. OP03 Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximab. (27th May 2021)

Authors:
Kennedy, N A; Goodhand, J; Bewshea, C; Nice, R; Chee, D; Lin, S; Chanchlani, N; Butterworth, J; Cooney, R; Croft, N; Hart, A; Irving, P; Kok, K; Lamb, C; Limdi, J; MacDonald, J; McGovern, D; Mehta, S; Murray, C; Patel, K
Journal:
Journal of Crohn's and colitis
Issue:
Volume 15(2021)Supplement 1
Page Start:
S002
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

23. OP15 Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?. (25th January 2019)

Authors:
Burisch, J; Vardi, H; Schwartz, D; Krznaric, Z; Lakatos, P L; Fumery, M; Kupcinskas, L; Magro, F; Belousova, E; Oksanen, P; Arebi, N; Langholz, E; Turcan, S; D'Inca, R; Hernandez, V; Valpiani, D; Vegh, Z; Giannotta, M; Katsanos, K H; Duricova, D
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S009
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

24. OP18 Disease course of Crohn's disease during the first ten years following diagnosis in a prospective European population-based inception cohort – the Epi-IBD cohort. (30th January 2023)

Authors:
Wewer, M D; Salupere, R; Kievit, H A L; Nielsen, K R; Midjord, J; Domislovic, V; Krznarić, Ž; Pedersen, N; Kjeldsen, J; Eriksson, C; Halfvarson, J; Talbot, A; Sebastian, S; Goldis, A; Misra, R; Arebi, N; Ilus, T; Oksanen, P; Neuman, A; Andersen, V
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i25
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

25. OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab. (21st January 2022)

Authors:
Alexander, J; Kennedy, N; Ibraheim, H; Anandabaskaran, S; Saifuddin, A; Castro Seoane, R; Liu, Z; Nice, R; Bewshea, C; D'Mello, A; Constable, L; Jones, G R; Balarajah, S; Fiorentino, F; Sebastian, S; Irving, P M; Hicks, L; Williams, H; Kent, A; Linger, R
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i022
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

26. OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients. (21st January 2022)

Authors:
Lin, S; Kennedy, N A; Saifuddin, A; Muñoz Sandoval, D; Reynolds, C J; Seoane, R C; Kottoor, S H; Pieper, F P; Lin, K M; Butler, D K; Chanchlani, N; Nice, R; Chee, D; Bewshea, C; Janjua, M; McDonald, T J; Sebastian, S; Alexander, J L; Constable, L; Lee, J C
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i023
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

27. OP24 Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study. (30th January 2023)

Authors:
Liu, Z; Le, K; Zhou, X; Alexander, J; Lin, S; Bewshea, C; Chanchlani, N; Nice, R; McDonald, T; Lamb, C; Sebastian, S; Kok, K; Lees, C; Hart, A; Pollok, R; Boyton, R; Altmann, D; Pollock, K; Goodhand, J; Kennedy, N
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i32
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

28. OP33 Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO). (30th January 2023)

Authors:
Raine, T; Vaja, S; Subramanian, S; Brezina, B; Probert, C S; Steel, A; Lofthouse, M; Speight, R A; Lamb, C; Sebastian, S; Kane, J; Thut, J; Din, S; Arnott, I; Smith, L; Galea, J; Hendy, P; Flores, L; Selinger, C; Onoviran, F
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i43
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

29. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission. (18th May 2017)

Authors:
Brooks, A J; Sebastian, S; Cross, S S; Robinson, K; Warren, L; Wright, A; Marsh, A M; Tsai, H; Majeed, F; McAlindon, M E; Preston, C; Hamlin, P J; Lobo, A J
Journal:
Journal of Crohn's and colitis
Issue:
Volume 11:Number 12(2017:Dec.)
Page Start:
1456
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗